CN112151173A - Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease - Google Patents
Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease Download PDFInfo
- Publication number
- CN112151173A CN112151173A CN202010949549.0A CN202010949549A CN112151173A CN 112151173 A CN112151173 A CN 112151173A CN 202010949549 A CN202010949549 A CN 202010949549A CN 112151173 A CN112151173 A CN 112151173A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- score
- clinical
- sex
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Abstract
The invention relates to the technical field of life medicine, in particular to an application evaluation model of immune state of T lymphocytes of hepatitis B liver diseases and a construction method thereof, which comprises the following steps of collecting peripheral blood of a hepatitis B patient, and separating the T lymphocytes by using immunomagnetic beads; detecting the expression level of the separated T lymphocyte surface antigen by adopting a chemiluminescence immunoassay method; detecting the expression level of liver function related protein in peripheral blood of hepatitis B patient by adopting a biochemical experiment method; calculating the correlation between the expression level of the T lymphocyte surface antigen, the expression level of the liver function related protein and the clinical expression of the hepatitis B patient; and selecting indexes with high correlation to establish a clinical scoring equation. The invention adopts a chemiluminescence method and a biochemical experiment method to quickly detect clinical indexes, thereby establishing an application evaluation model of the immune state of the hepatitis B liver disease T cells.
Description
Technical Field
The invention relates to the technical field of life medicine, in particular to an application evaluation model of immune state of hepatitis B liver disease T lymphocytes and a construction method thereof.
Background
The hepatitis B refers to the hepatitis B virus which is detected as positive and has chronic hepatitis manifestations clinically. Clinically, it is manifested as lassitude, aversion to food, nausea, abdominal distention, and pain in the liver. Liver is large, medium hardness, and slight tenderness. The serious disease may be accompanied by facial appearance of chronic liver disease, spider nevus, hepatomegaly, splenomegaly, and abnormal or persistent liver function. According to clinical manifestations, the disease is divided into mild, moderate and severe. The chronic hepatitis B virus carrier is a person with positive hepatitis B virus detection, no chronic hepatitis symptom, no abnormality in serum ALT and AST after continuous follow-up for more than 3 times within 1 year and normal liver histology examination. The world health organization international cancer research institute publishes the list of carcinogens for the initial reference, hepatitis B virus (chronic infection) in a category of carcinogen list.
The T lymphocyte is derived from the pluripotent stem cell of the bone marrow, and the mature T cell distributes to the thymus dependent area of the peripheral immune organ through the blood stream for colonization, and can be recycled through the lymphatic vessel, the peripheral blood, the tissue fluid and the like to play the functions of cellular immunity, immunoregulation and the like. The recycling of T cells facilitates the wide exposure to antigenic substances entering the body, enhances the immune response and maintains the immunological memory for a longer period. There are many different markers on the cell membrane of T cells, mainly surface antigens and surface receptors. These surface markers are macroprotein molecules bound to the cell membrane. T cells can be classified into cytotoxic T cells, helper T cells, regulatory/suppressor T cells and memory T cells according to function and surface markers.
Research shows that the therapeutic effect of hepatitis B has higher correlation with the immune state of T lymphocytes of patients, and strong T lymphocyte function is helpful for thoroughly eliminating hepatitis B virus, so that the evaluation of the immune state of the T lymphocytes has extremely high applicability in the therapeutic process of hepatitis B liver diseases, but the existing T lymphocyte immune state evaluation model has complex construction process and low applicability.
Disclosure of Invention
Aiming at the technical problems in the prior art, the invention provides a simple and high-applicability model for evaluating the immune state of the hepatitis B liver disease T lymphocyte and a construction method thereof.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
the construction method of the model for evaluating the immune state of the T cells of the hepatitis B liver disease comprises the following steps,
(1) collecting peripheral blood of a hepatitis B patient, and performing T lymphocyte magnetic bead separation by adopting immunomagnetic beads;
(2) detecting the expression level of the separated T lymphocyte surface antigen by adopting a chemiluminescence immunoassay method,
wherein the T lymphocyte surface antigen comprises CD3, CD4, CD 8;
(3) detecting the expression level of liver function related protein in peripheral blood of hepatitis B patient by biochemical experiment,
wherein the liver function-related protein comprises expression levels of ALT, AST, ALP, GGT, TP, ALB, GLB, AFP;
(4) performing grouping statistical analysis on the tested hepatitis B patients according to sex, age and clinical manifestations, and calculating the correlation between the expression level of T lymphocyte surface antigen, the expression level of liver function-related protein and the clinical manifestations of the hepatitis B patients of different sexes and ages;
(5) selecting high-correlation indexes to establish a clinical scoring equation for evaluating the immune state of the T lymphocytes,
wherein the clinical score equation is 1.351Age +2.563Sex +1.028CD3+1.765CD4+0.861CD8+0.253(CD4/CD8) +0.231ALT +0.564TP +1.231ALB +0.156 AFP-153.263.
Further, Age in the clinical score equation refers to the Age assigned score of hepatitis b patients, which is shown in the following table:
| age (year of old) | ＜20 | ≥20，＜40 | ≥40，＜60 | ≥60 |
| Age assigned score (Age) | 2.5 | 1.5 | 0.5 | 0.2 |
。
Further, in the clinical scoring equation, Sex refers to the gender assigned score of hepatitis B patients, and the gender assigned score is as follows:
| sex | Male sex | Female with a view to preventing the formation of wrinkles |
| Sex assigned score (Sex) | 0.5 | 1 |
。
Further characterized in that said CD3, CD4, CD8, CD4/CD8, ALT, TP, ALB, and AFP in said clinical scoring equation refer to CD3 assigned score, CD4 assigned score, CD8 assigned score, CD4/CD8 assigned score, ALT assigned score, TP assigned score, ALB assigned score, and AFP assigned score, respectively, as shown in the following table:
the invention also provides application of the model construction method for evaluating the immune state of the T cells of the hepatitis B liver disease in preparing products for evaluating the immune state of the T lymphocytes of the hepatitis B liver disease.
Compared with the prior art, the invention has the beneficial effects that:
the invention adopts a chemiluminescence method and a biochemical experiment method to quickly detect the expression level of the T lymphocyte surface antigen and the expression level of the liver function related protein in the peripheral blood of a hepatitis B patient, and counts the correlation between the clinical indexes and clinical expressions, thereby establishing the application evaluation model of the immune state of the hepatitis B liver disease T cells.
Detailed Description
The embodiments of the invention have been described in detail, but the invention can be implemented in many different ways, which are defined and covered by the claims.
Example 1
1. Clinical testing
1.1, 118 hepatitis B patients (58 males and 60 females) are selected as experimental objects, peripheral blood of the hepatitis B patients to be tested is respectively adopted at different treatment stages, and immunomagnetic beads are adopted for T lymphocyte magnetic bead separation;
1.2 detecting the expression level of separated T lymphocyte surface antigens CD3, CD4 and CD8 by adopting a chemiluminescence immunoassay method,
1.3 detecting the expression level of liver function related proteins ALT, AST, ALP, GGT, TP, ALB, GLB and AFP in peripheral blood of a hepatitis B patient by adopting a biochemical experiment method,
1.4 recording the sex, age and clinical manifestations of the hepatitis B patients tested at different treatment stages;
1.5 analyzing the correlation between the clinical indexes tested in the steps 1.2 and 1.3 and the 1.4 recorded indexes;
1.6 selecting the index with high correlation to establish a clinical scoring equation for evaluating the immune state of the T lymphocyte and further guiding the treatment of hepatitis B liver diseases.
2. Analysis of results
Carrying out correlation analysis on the expression levels of T lymphocyte surface antigens CD3, CD4 and CD8, the expression levels of liver function related proteins ALT, AST, ALP, GGT, TP, ALB, GLB and AFP in peripheral blood of a hepatitis B patient, the Sex, the Age and the improvement condition of clinical manifestations at different stages of the hepatitis B patient, finding high correlation indexes which can be established by an application evaluation model of the immune state of the hepatitis B liver disease T cells and are respectively Age, Sex, CD3, CD4, CD8, CD4/CD8, ALT, TP and ALB, and further obtaining a clinical score equation of 1.351Age +2.563Sex +1.028CD3+1.765CD4+0.861CD8+0.253(CD4/CD8) +0.231 +0.564TP +1.231ALB + 0.156-153.263 and a cut AFP: 26.597.
age in the clinical score equation refers to the Age assigned score for patients with hepatitis b, which is given in the following table:
| age (year of old) | ＜20 | ≥20，＜40 | ≥40，＜60 | ≥60 |
| Age assigned score (Age) | 2.5 | 1.5 | 0.5 | 0.2 |
。
In the clinical scoring equation, Sex refers to the gender assigned score of hepatitis B patients, which is shown in the following table:
| sex | Male sex | Female with a view to preventing the formation of wrinkles |
| Sex assigned score (Sex) | 0.5 | 1 |
。
The CD3, CD4, CD8, CD4/CD8, ALT, TP, ALB, and AFP scores in the clinical scoring equation refer to CD3 assigned score, CD4 assigned score, CD8 assigned score, CD4/CD8 assigned score, ALT assigned score, TP assigned score, ALB assigned score, and AFP assigned score, respectively, as shown in the following table:
| clinical index | Test value | Assigned score | Clinical index | Test value | Assigned score |
| CD3 | X1 | X1/％ | ALT | Y1 | Y1/μ/L |
| CD4 | X2 | X2/％ | TP | Y2 | Y2/g/L |
| CD8 | X3 | X3/％ | ALB | Y3 | Y3/g/L |
| CD4/CD8 | X4 | X4 | AFP | Y4 | Y4/mg/L |
。
3. Clinical application
The obtained clinical scoring equation is used for evaluating the immune state of the T lymphocyte of the hepatitis B liver disease and further guiding medication according to the immune state; the results of hepatitis B virus detection in different treatment stages show that the clinical scoring equation of the invention is applied to guide medication, and the clearance rate of hepatitis B virus in each treatment stage can be obviously improved.
The above description is only a preferred embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications and variations that can be made by the present invention in the specification or directly or indirectly applied to other related technical fields are included in the scope of the present invention.
Claims (5)
1. The construction method of the model for evaluating the immune state of the T cells of the hepatitis B liver disease is characterized by comprising the following steps,
(1) collecting peripheral blood of a hepatitis B patient, and performing T lymphocyte magnetic bead separation by adopting immunomagnetic beads;
(2) detecting the expression level of the separated T lymphocyte surface antigen by adopting a chemiluminescence immunoassay method,
wherein the T lymphocyte surface antigen comprises CD3, CD4, CD 8;
(3) detecting the expression level of liver function related protein in peripheral blood of hepatitis B patient by biochemical experiment,
wherein the liver function-related protein comprises expression levels of ALT, AST, ALP, GGT, TP, ALB, GLB, AFP;
(4) performing grouping statistical analysis on the tested hepatitis B patients according to sex, age and clinical manifestations, and calculating the correlation between the expression level of T lymphocyte surface antigen, the expression level of liver function-related protein and the clinical manifestations of the hepatitis B patients of different sexes and ages;
(5) selecting high-correlation indexes to establish a clinical scoring equation for evaluating the immune state of the T lymphocytes,
wherein the clinical score equation is 1.351Age +2.563Sex +1.028CD3+1.765CD4+0.861CD8+0.253(CD4/CD8) +0.231ALT +0.564TP +1.231ALB +0.156 AFP-153.263.
2. The method for constructing a model for evaluating the T cell immune status of hepatitis B liver disease according to claim 1, wherein Age in the clinical score equation refers to the score assigned to the Age of hepatitis B patient, and the score assigned to the Age is as follows:
。
3. The method for constructing a model for evaluating the T cell immune status of hepatitis B liver disease according to claim 1, wherein Sex in the clinical scoring equation refers to the Sex assigned score of hepatitis B patient, and the Sex assigned score is as follows:
。
4. The method for constructing the model for assessing the immune status of T lymphocytes resulting from hepatitis b liver disease according to claim 1, wherein said clinical score equations for CD3, CD4, CD8, CD4/CD8, ALT, TP, ALB and AFP refer to the score of CD3 assignment, the score of CD4 assignment, the score of CD8 assignment, the score of CD4/CD8 assignment, the score of ALT assignment, the score of TP assignment, the score of ALB and the score of AFP assignment, respectively, as shown in the following table:
。
5. The use of the model construction method for assessing the immune status of hepatitis B liver disease T cells according to claims 1 to 4 in the preparation of products for assessing the immune status of hepatitis B liver disease T lymphocytes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010949549.0A CN112151173A (en) | 2020-09-10 | 2020-09-10 | Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010949549.0A CN112151173A (en) | 2020-09-10 | 2020-09-10 | Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112151173A true CN112151173A (en) | 2020-12-29 |
Family
ID=73889829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010949549.0A Withdrawn CN112151173A (en) | 2020-09-10 | 2020-09-10 | Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112151173A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113421627A (en) * | 2021-05-11 | 2021-09-21 | 深圳市罗湖区人民医院 | System for evaluating anti-aging effect of drug on NK (natural killer) cells in vitro |
-
2020
- 2020-09-10 CN CN202010949549.0A patent/CN112151173A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113421627A (en) * | 2021-05-11 | 2021-09-21 | 深圳市罗湖区人民医院 | System for evaluating anti-aging effect of drug on NK (natural killer) cells in vitro |
| CN113421627B (en) * | 2021-05-11 | 2023-04-07 | 深圳市罗湖区人民医院 | System for evaluating anti-aging effect of drug on NK (natural killer) cells in vitro |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis | |
| Liu et al. | Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood | |
| Kefalakes et al. | Liver-resident bystander CD8+ T cells contribute to liver disease pathogenesis in chronic hepatitis D virus infection | |
| Gironi et al. | A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis | |
| CN108463228A (en) | The prognosis and treatment of squamous cell carcinoma | |
| RU2583939C1 (en) | Method for laboratory diagnosis of stages of hepatic fibrosis in chronic viral hepatitis c | |
| CN110548048B (en) | Use of hematopoietic stem cells for preparing a formulation for treating viral diseases | |
| CN112151173A (en) | Method for constructing model for evaluating applicability of T cell immune state of hepatitis B liver disease | |
| Liang et al. | TLR3 and TLR4 but not TLR2 are involved in Vogt-Koyanagi-Harada disease by triggering proinflammatory cytokines production through promoting the production of mitochondrial reactive oxygen species | |
| Sasaki et al. | In vitro marker gene expression analyses in human peripheral blood mononuclear cells: A tool to assess safety of influenza vaccines in humans | |
| EP3589952A1 (en) | Improved kits and assays to detect circulating multiple myeloma cells from blood | |
| CN110295228A (en) | Detect application of the substance of GATA2 in preparation diagnostic activities kit lungy | |
| Duncan | Cutaneous lymphoma: understanding the new classification schemes | |
| CN110161235B (en) | Application of three serum proteins in ankylosing spondylitis diagnosis | |
| CN108490176A (en) | Application of the phosphorylated neurofilament ferritin heavy chain in Lues Assay | |
| CN112180093B (en) | Critical disease mortality diagnostic biomarker tenascin-c and application thereof | |
| CN107375950B (en) | Recombinant Gal-1 allergic environment immune tolerance induction model and establishment method | |
| Al-Nuri | The Frequency of Blood Donors and Polycythemia among General Population in Nineveh Governorate, Iraq. | |
| JP2010017130A (en) | Method for separating pathogenic cell of autoimmune disease, and method for diagnostic assistance to autoimmune disease | |
| Zhong et al. | Isolation of microglia from retinas of chronic ocular hypertensive rats | |
| US20220221462A1 (en) | Marker for diagnosing colorectal cancer and method for providing information required for diagnosis of colorectal cancer | |
| Ali et al. | Evaluation of TLR-2 sera levels in a sample of Iraqi pulmonary TB patients | |
| Marlentine et al. | The relationship between ABO blood group typing with tinea corporis and or tinea cruris in Tanjung Gusta Prison, Medan-Indonesia | |
| CN108728542A (en) | Detect the preparation and its application process of long-chain non-coding RNA BC200 | |
| Rusanova et al. | AB0110 DETERMINING THE AMOUNT OF COPPER–CONTAINING PROTEIN, ITS BIOCHEMICAL AND IMMUNOLOGIC ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201229 |
|
| WW01 | Invention patent application withdrawn after publication |